A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of FZ008-145 Solution in Healthy Subjects (Part A); A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of FZ008-145 Tablet in Healthy Subjects (Part B); A Randomized, Open-label, 2-period, 2-treatment (2×2) Crossover Study to Assess the Food Effect on Bioavailability of FZ008-145 Tablet in Healthy Subjects (Part C)
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs FZ 008 (Primary) ; FZ 008 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangzhou Fermion Technology
- 18 Nov 2024 New trial record